
Opinion|Videos|March 28, 2025
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Author(s)Lisa Swanson, MD, FAAD
Lisa Swanson, MD, FAAD, discusses how factors such as the safety profile, efficacy, age-appropriate dosing, and potential long-term effects of ruxolitinib cream would be crucial in determining its place in treatment for young children.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- When considering an emerging topical JAK inhibitor like ruxolitinib cream for young children, what factors would be most important to you in determining its place in treatment?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5























